Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Review

Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials

Authors: Jeremy Howick, Rebecca Webster, Nigel Kirby, Kerry Hood

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Trial participants in placebo groups report experiencing adverse events (AEs). Existing systematic reviews have not been synthesized, leaving questions about why these events occur as well as their prevalence across different conditions unanswered.

Objectives

(1)
To synthesize the evidence of prevalence of AEs in trial placebo groups across different conditions.
 
(2)
To compare AEs in trial placebo groups with AEs reported in untreated groups within a subset of randomized trials.
 

Search methods

We searched PubMed for records with the word “nocebo” in the title and “systematic” in any field. We also contacted experts and hand-searched references of included studies.

Study eligibility

We included any systematic review of randomized trials where nocebo effects were reported. We excluded systematic reviews of non-randomized studies.

Participants and interventions

We included studies in any disease area.

Study appraisal and synthesis methods

We appraised the quality of the studies using a shortened version of the Assessment of Multiple Systematic Reviews tool (AMSTAR) tool. We reported medians and interquartile ranges (IQRs) of AEs. Among the trials within the review that included untreated groups, we compared the prevalence of AEs in untreated groups with the prevalence of AEs in placebo groups.

Results

We identified 20 systematic reviews. These included 1271 randomized trials and 250,726 placebo-treated patients. The median prevalence of AEs in trial placebo groups was 49.1% (IQR 25.7–64.4%). The median rate of dropouts due to AEs was 5% (IQR 2.28–8.4%). Within the 15 of trials that reported AEs in untreated groups, we found that the AE rate in placebo groups (6.51%) was higher than that reported in untreated groups (4.25%).

Limitations

This study was limited by the quality of included reviews and the small number of trials that included untreated groups.

Conclusions and implications of key findings

AEs in trial placebo groups are common and cannot be attributed entirely to natural history. Trial methodologies that reduce AEs in placebo groups while satisfying the requirement of informed consent should be developed and implemented.
Appendix
Available only for authorised users
Literature
1.
Jensen KB, Kaptchuk TJ, Chen X, Kirsch I, Ingvar M, Gollub RL, et al. A neural mechanism for nonconscious activation of conditioned placebo and nocebo responses. Cereb Cortex. 2014;25(10):3903–10.
2.
Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A. 2012;109(39):15959–64.CrossRefPubMedPubMedCentral
3.
Howick J. Saying things the “right” way: avoiding “nocebo” effects and providing full informed consent. Am J Bioeth. 2012;12(3):33–4.CrossRefPubMed
4.
Mercado R, Constantoyannis C, Mandat T, Kumar A, Schulzer M, Stoessl AJ, et al. Expectation and the placebo effect in Parkinson’s disease patients with subthalamic nucleus deep brain stimulation. Mov Disord. 2006;21(9):1457–61.CrossRefPubMed
5.
Whitford HS, Olver IN. When expectations predict experience: the influence of psychological factors on chemotherapy toxicities. J Pain Symptom Manag. 2012;43(6):1036–50.CrossRef
6.
Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16(11):1277–83.CrossRefPubMed
7.
Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147(2):260–71.CrossRefPubMed
8.
Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther. 1987;42(3):250–3.CrossRefPubMed
9.
Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol. 1997;50(12):1311–8.CrossRefPubMed
10.
11.
Mickan S, Tilson JK, Atherton H, Roberts NW, Heneghan C. Evidence of effectiveness of health care professionals using handheld computers: a scoping review of systematic reviews. J Med Internet Res. 2013;15(10):111–9.CrossRef
12.
Amanzio M. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146(3):261–9.CrossRefPubMed
13.
Hauser W, Bartram C, Bartram-Wunn E, Tolle T. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain. 2012a;28(5):437–51.CrossRefPubMed
14.
Hauser W, Sarzi-Puttini P, Tolle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol. 2012b;30(6 Suppl 74):78–87.PubMed
15.
Koog YH, Lee JS, Wi H. Clinically meaningful nocebo effect occurs in acupuncture treatment: a systematic review. J Clin Epidemiol. 2014;67(8):858–69.CrossRefPubMed
16.
17.
Mahr A, Golmard C, Pham E, Iordache L, Deville L, Faure P. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. Pharmacoepidemiol Drug Saf. 2017;26(7):731–41.CrossRefPubMed
18.
Meister R, Jansen A, Harter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis. J Affect Disord. 2017;215:288–98.CrossRefPubMed
19.
Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31(5):550–61.CrossRefPubMed
20.
Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol. 2012;19(5):672–80.CrossRefPubMed
21.
Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014;215(1):82–6.CrossRefPubMed
22.
Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16(7):816–28.CrossRefPubMed
23.
Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012;259(3):436–47.CrossRefPubMed
24.
Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006;166(2):155–60.CrossRefPubMed
25.
Rief W, Nestoriuc Y, von Lilienfeld-Toal A, Dogan I, Schreiber F, Hofmann SG, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 2009;32(11):1041–56.CrossRefPubMed
26.
Rojas-Mirquez JC, Rodriguez-Zuniga MJ, Bonilla-Escobar FJ, Garcia-Perdomo HA, Petkov M, Becerra L, et al. Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis. Front Behav Neurosci. 2014;8:375.CrossRefPubMedPubMedCentral
27.
Shafiq F, Mitsikostas DD, Zis P. Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials. Amyotrop Lateral Scler Frontotemporal Degener. 2017;18(7–8):576–82.CrossRef
28.
Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, et al. Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis. Neurology. 2017;88(23):2216–24.CrossRefPubMed
29.
Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis. Eur J Neurol. 2013;20(3):527–33.CrossRefPubMed
30.
Zis P, Mitsikostas DD. Nocebo in Alzheimer’s disease; meta-analysis of placebo-controlled clinical trials. J Neurol Sci. 2015;355(1–2):94–100.CrossRefPubMed
31.
Zis P, Shafiq F, Mitsikostas DD. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials. Seizure. 2017;45:95–9.CrossRefPubMed
32.
Barrett B, Brown R, Rakel D, Mundt M, Bone K, Barlow S, et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.CrossRefPubMedPubMedCentral
33.
Howick J, Moscrop A, Mebius A, Fanshawe TR, Lewith G, Bishop FL, et al. Effects of empathic and positive communication in healthcare consultations: a systematic review and meta-analysis. J R Soc Med. 2018;111:240–52.CrossRefPubMedPubMedCentral
34.
Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334–55.CrossRefPubMed
35.
36.
Wells R, Kaptchuk TJ. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth. 2012;2(3):22–9.CrossRef
Metadata
Title
Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials
Authors
Jeremy Howick
Rebecca Webster
Nigel Kirby
Kerry Hood
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-3042-4

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

Clinical research on the efficacy and safety of thread-embedding acupuncture for treatment of herniated intervertebral disc of the lumbar spine: a protocol for a multicenter, randomized, patient–assessor blinded, controlled, parallel, clinical trial

Study protocol

Effectiveness of the KENKOJISEICHI local revitalization system on cognitive function change in older adults with mild cognitive impairment: study protocol for a randomized controlled trial

Study protocol

Prevention of Early Postoperative Decline (PEaPoD): protocol for a randomized, controlled feasibility trial

Study protocol

A couple-based HIV prevention intervention for Latino men who have sex with men: study protocol for a randomized controlled trial

Study protocol

Management of medial humeral epicondyle fractures in children: a structured review protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey

Study protocol

Cerebral microembolism in the critically ill with acute kidney injury (COMET-AKI trial): study protocol for a randomized controlled clinical trial